Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma

Journal of Asthma

Volumn 47, Issue 2, 2010, Pages 217-223

  O'Connor, Richard D ^a   Patrick, Donald L ^b   Parasuraman, Bhash ^c   Martin, Paula ^d   Goldman, Mitchell ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Health Economics and Outcomes Research   (United States)

^d Biostatistics   (United States)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Budesonide; Fluticasone; Formoterol; Patient reported outcomes; Salmeterol

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE PLUS SALMETEROL;

ADULT; AGED; ARTICLE; ASTHMA; ASTHMA QUALITY OF LIFE QUESTIONNAIRE; ASTHMA TREATMENT SATISFACTION MEASURE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE SEVERITY; ENVIRONMENTAL EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METERED DOSE INHALER; ONSET OF EFFECT QUESTIONNAIRE; OUTCOME ASSESSMENT; PATIENT SATISFACTION; POWDER INHALER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF REPORT; STRUCTURED QUESTIONNAIRE;

ADOLESCENT; ADULT; AGED; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BUDESONIDE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; HUMANS; MALE; METERED DOSE INHALERS; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77249141084     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770900903497154     Document Type: Article

References (26)

1. Global Initiative for Asthma. Global strategy for asthma management and prevention. Bethesda,MD: NationalHeart, Lung, andBlood Institute; 2006. NIH Publication No. 02-3659.
2. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Bethesda,MD: National Heart, Lung, and Blood Institute; 2007. NIH Publication No. 07-4051.
3. Busse WW, Shah SR, Somerville L, Parasuraman B, Martin P, GoldmanM. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients. J Allergy Clin Immunol 2008; 121:1407-1414, e1401-1406.
4. Marquis P,Trudeau E. Quality of life and patient satisfaction:Two important aspects in asthma therapy. Curr Opin Pulm Med 2001; 7(suppl 1):S18-S20.
5. Smith NA, Ley P, Seale JP, Shaw J. Health beliefs, satisfaction and compliance. Patient Educ Couns 1987; 10:279-286.
6. Osman LM. How do patients' views about medication affect their selfmanagement in asthma? Patient Educ Couns 1997; 32:S43-S49.
7. Adams RJ, Smith BJ, Ruffin RE. Factors associated with hospital admissions and repeat emergency department visits for adults with asthma. Thorax 2000; 55:566-573.
8. Morice AH, Peterson S, Beckman O, Osmanliev D. Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma. Int J Clin Pract 2007; 61:1874-1883.
9. Chervinsky P, Baker J, Bensch G, Parasuraman B, Boggs R, Martin P, O'Dowd L. Patient-reported outcomes in adults with moderate to severe asthma after use of budesonide and formoterol administered via 1 pressurized metered-dose inhaler. Ann Allergy Asthma Immunol 2008; 101:463-473.
10. Murphy K, Nelson H, Parasuraman B, Boggs R, Miller C, O'Dowd L. The effect of budesonide and formoterol in one pressurized metered-dose inhaler on patient-reported outcomes in adults with mild-to-moderate persistent asthma. Curr Med Res Opin 2008; 24:879-894.
11. Juniper EF, Buist AS, Cox FM, Ferrie PJ, King DR. Validation of a standardized version of the Asthma Quality of Life Questionnaire. Chest 1999; 115:1265-1270.
12. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14:902-907.
13. Juniper EF, SvenssonK,MorkAC, Stahl E.Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005; 99:553-558.
14. Martin ML, Patrick DL, Bushnell DM, Meltzer EO, Gutierrez B, Parasuraman B. The Asthma Treatment Satisfaction Measure (ATSM) for patients with asthma. Curr Med Res Opin 2009; 25:2495-2506.
15. Patrick DL, Martin ML, Bushnell DM, Pesa J. Measuring satisfaction with migraine treatment: Expectations, importance, outcomes, and global ratings. Clin Ther 2003; 25:2920-2935.
16. Martin ML, Patrick DL, Bushnell DM, Gandra SR, Gilchrist K. Further validation of an individualized migraine treatment satisfaction measure. Value Health 2008; 11:904-912.
17. Leidy NK, Mathias SD, Parasuraman BM, Patrick DL, Pathak D. Development and validation of an onset of effect questionnaire for patients with asthma. Allergy Asthma Proc 2008; 29:590-599.
18. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol 1994; 47:81-87.
19. Buhl R, Kardos P, Richter K, Meyer-Sabellek W, Bruggenjurgen B, Willich SN, Vogelmeier C. The effect of adjustable dosing with budesonide/ formoterol on health-related quality of life and asthma control compared with fixed dosing. Curr Med Res Opin 2004; 20:1209-1220.
20. Smith JR, Mildenhall S, Noble M, Mugford M, Shepstone L, Harrison BD. Clinician-assessed poor compliance identifies adults with severe asthma who are at risk of adverse outcomes. J Asthma 2005; 42:437-445.
21. Hampel FC, Martin P, Mezzanotte WS. Early bronchodilatory effects of budesonide/formoterol pMDI compared with fluticasone/salmeterol DPI and albuterol pMDI: 2 randomized controlled trials in adults with persistent asthma previously treated with inhaled corticosteroids. J Asthma 2008; 45:265-272.
22. Palmqvist M, Arvidsson P, Beckman O, Peterson S, Lotvall J. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther 2001; 14:29-34.
23. Van Der Woude HJ, Boorsma M, Bergqvist PB, Winter TH, Aalbers R. Budesonide/formoterol in a single inhaler rapidly relieves methacholineinduced moderate-to-severe bronchoconstriction. Pulm Pharmacol Ther 2004; 17:89-95.
24. Palmqvist M, PerssonG, Lazer L, Rosenborg J, Larsson P, Lotvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients:Onset of action, duration of effect and potency. Eur Respir J 1997; 10:2484-2489.
25. Bender BG, Long A, Parasuraman B, Tran ZV. Factors influencing patient decisions about the use of asthma controller medication. Ann Allergy Asthma Immunol 2007; 98:322-328.
26. Hauber AB, Mohamed AF, Johnson FR, Meddis D, Wagner S, O'Dowd L. Quantifying asthma patient preferences for onset of effect of combination inhaled corticosteroids and long-acting beta2-agonist maintenance medications. Allergy Asthma Proc 2009; 30:139-147.